Heparin
Heparin is an anticoagulant given by injection. The US label read, for Heparin Sodium Injection, lists these uses: prophylaxis and treatment of venous thrombosis and pulmonary embolism; prevention of postoperative deep venous thrombosis and pulmonary embolism in people having major abdominothoracic surgery or otherwise at risk; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies; prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism; and use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures. The label says heparin does not dissolve existing clots.
Also called Heparin sodium
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 5224; UNII ZZ45AB24CA is the UNII of heparin sodium, the form the label names, and is a broad match. MeSH descriptor D006493 is Heparin. Class: Unfractionated Heparin (FDA established pharmacologic class, RxClass), which this atlas files under the class page for heparins and low-molecular-weight heparins. The label read is the Fresenius Kabi USA, LLC label for Heparin Sodium Injection, application NDA017029, effective 2026-04-30 in openFDA. Heparin is sold by several sponsors under several applications; other labels were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 16 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 16
- Phase 3 or 4
- 16
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|
| Phase 3 | 1 | 3 | 1 | 2 | 7 |
| Phase 4 | 0 | 2 | 1 | 6 | 9 |
| All phases | 1 | 5 | 2 | 8 | 16 |
Conditions these trials study
- Heart attack (myocardial infarction)
- ST-elevation heart attack (STEMI)
- Pulmonary embolism
- Acute coronary syndrome
- Chronic kidney disease (CKD)
- Deep vein thrombosis
- Ischemic stroke
- Stroke
- Coronary artery disease
- Heart failure
Sponsors with the most trials
- The First Affiliated Hospital of Dalian Medical University
- Centre Hospitalier Universitaire de Saint Etienne
- Changhai Hospital
- CorMedix Therapeutics
- Jesper Kjaergaard
About this drug
- Level
- Substance
- Mechanism
- The label says heparin acts through the plasma protein antithrombin III and has no fibrinolytic activity, so it does not lyse existing clots.
Classification codes
-
ZZ45AB24CA
Claims and evidence
Context People for whom the US label of heparin sodium injection lists an indication: venous thrombosis, pulmonary embolism, atrial fibrillation with embolization, consumptive coagulopathy, arterial and cardiac surgery, peripheral arterial embolism
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 6 inclusion criteria; exclusion criteria not stated
- Included
- Patients needing prophylaxis or treatment of venous thrombosis and pulmonary embolism
- Patients undergoing major abdominothoracic surgery, or otherwise at risk of thromboembolic disease, for prevention of postoperative deep venous thrombosis and pulmonary embolism
- Patients with atrial fibrillation with embolization
- Patients with acute or chronic consumptive coagulopathies (disseminated intravascular coagulation)
- Patients in arterial and cardiac surgery, or needing prophylaxis or treatment of peripheral arterial embolism
- Blood transfusions, extracorporeal circulation and dialysis procedures
- Excluded
- None stated
The US label of Heparin Sodium Injection, in the Fresenius Kabi USA, LLC version dated 2026-04-30 in openFDA, describes heparin as an anticoagulant and lists it for the prophylaxis and treatment of venous thrombosis and pulmonary embolism; the prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or otherwise at risk of thromboembolic disease; atrial fibrillation with embolization; the treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); the prevention of clotting in arterial and cardiac surgery; the prophylaxis and treatment of peripheral arterial embolism; and use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures.
Applies to Recipient not specified People for whom the US label of heparin sodium injection lists an indication: venous thrombosis, pulmonary embolism, atrial fibrillation with embolization, consumptive coagulopathy, arterial and cardiac surgery, peripheral arterial embolism
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; contraindications, doses, interactions, pregnancy and paediatric use and other warnings were not read. Labels differ between sponsors and change over time, and openFDA lists many heparin labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (9)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE (highlights)
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2026-04-30
- Source state
- Current
- Version fingerprint
ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, first bullet
- How it applies
- Label passage quoted in the research quote table (LB-05).
- Retrieved
- Source effective date
- 2026-04-30
- Source state
- Current
- Version fingerprint
ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, second bullet
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2026-04-30
- Source state
- Current
- Version fingerprint
ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, third bullet
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2026-04-30
- Source state
- Current
- Version fingerprint
ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, fourth bullet
- How it applies
- Label passage quoted in the research quote table (LB-08).
- Retrieved
- Source effective date
- 2026-04-30
- Source state
- Current
- Version fingerprint
ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, fifth bullet
- How it applies
- Label passage quoted in the research quote table (LB-09).
- Retrieved
- Source effective date
- 2026-04-30
- Source state
- Current
- Version fingerprint
ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, sixth bullet
- How it applies
- Label passage quoted in the research quote table (LB-10).
- Retrieved
- Source effective date
- 2026-04-30
- Source state
- Current
- Version fingerprint
ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, seventh bullet
- How it applies
- Label passage quoted in the research quote table (LB-11).
- Retrieved
- Source effective date
- 2026-04-30
- Source state
- Current
- Version fingerprint
ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260430.
- Retrieved
- Source effective date
- 2026-04-30
- Source state
- Current
- Version fingerprint
ff13980cb5d43441fb3aa10072a84173113a76115836af9d877f6e2708930777- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
DEFENCATH
No label from the application holder was found in the openFDA label dataset for application NDA214520. This page does not show another labeler's label in its place.
HEPARIN LOCK FLUSH
No label from the application holder was found in the openFDA label dataset for application NDA017064. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA004570. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA005521. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA017007. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA017029. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA017037. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA017486. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA017651. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA017780. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA017979. This page does not show another labeler's label in its place.
HEPARIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA201370. This page does not show another labeler's label in its place.
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA018609. This page does not show another labeler's label in its place.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA019042. This page does not show another labeler's label in its place.
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA019953. This page does not show another labeler's label in its place.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
No label from the application holder was found in the openFDA label dataset for application NDA018911. This page does not show another labeler's label in its place.
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA019339. This page does not show another labeler's label in its place.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA019802. This page does not show another labeler's label in its place.
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA018814. This page does not show another labeler's label in its place.
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA019805. This page does not show another labeler's label in its place.
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA019952. This page does not show another labeler's label in its place.
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA019134. This page does not show another labeler's label in its place.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA019135. This page does not show another labeler's label in its place.
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%
No label from the application holder was found in the openFDA label dataset for application NDA018916. This page does not show another labeler's label in its place.
LIQUAEMIN SODIUM
No label from the application holder was found in the openFDA label dataset for application NDA000552. This page does not show another labeler's label in its place.
PANHEPRIN
No label from the application holder was found in the openFDA label dataset for application NDA005264. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA000552 - Approval
NDA004570 - Approval
NDA005264 - Approval
NDA005521 - Approval
NDA017029 - Approval
NDA017037 - Approval
NDA017007 - Approval
NDA017064 - Approval
NDA017486 - Approval
NDA017651 - Approval
NDA017780 - Approval
NDA017979 - Supplemental approval
NDA005264 - Approval
NDA018609 - Approval
NDA018814 - Supplemental approval
NDA017651 - Supplemental approval
NDA017979 - Approval
NDA018916 - Supplemental approval
NDA017651 - Approval
NDA018911 - Approval
NDA019339 - Approval
NDA019042 - Approval
NDA019134 - Approval
NDA019135 - Supplemental approval
NDA005264 - Supplemental approval
NDA018814 - Supplemental approval
NDA017029 - Supplemental approval
NDA000552 - Approval
NDA019805 - Supplemental approval
NDA018916 - Approval
NDA019802 - Approval
NDA019952 - Approval
NDA019953 - Approval
NDA201370 - Approval
NDA214520
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists prophylaxis and treatment of venous thrombosis and pulmonary embolism as an indication: Pulmonary embolism
Applies to Recipient not specified People for whom the US label of heparin sodium injection lists an indication: venous thrombosis, pulmonary embolism, atrial fibrillation with embolization, consumptive coagulopathy, arterial and cardiac surgery, peripheral arterial embolism
The US label of Heparin Sodium Injection, in the Fresenius Kabi USA, LLC version dated 2026-04-30 in openFDA, describes heparin as an anticoagulant and lists it for the prophylaxis and treatment of venous thrombosis and pulmonary embolism; the prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or otherwise at risk of thromboembolic disease; atrial fibrillation with embolization; the treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); the prevention of clotting in arterial and cardiac surgery; the prophylaxis and treatment of peripheral arterial embolism; and use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; contraindications, doses, interactions, pregnancy and paediatric use and other warnings were not read. Labels differ between sponsors and change over time, and openFDA lists many heparin labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists prevention of postoperative deep venous thrombosis as an indication: Deep vein thrombosis
Applies to Recipient not specified People for whom the US label of heparin sodium injection lists an indication: venous thrombosis, pulmonary embolism, atrial fibrillation with embolization, consumptive coagulopathy, arterial and cardiac surgery, peripheral arterial embolism
The US label of Heparin Sodium Injection, in the Fresenius Kabi USA, LLC version dated 2026-04-30 in openFDA, describes heparin as an anticoagulant and lists it for the prophylaxis and treatment of venous thrombosis and pulmonary embolism; the prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or otherwise at risk of thromboembolic disease; atrial fibrillation with embolization; the treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); the prevention of clotting in arterial and cardiac surgery; the prophylaxis and treatment of peripheral arterial embolism; and use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; contraindications, doses, interactions, pregnancy and paediatric use and other warnings were not read. Labels differ between sponsors and change over time, and openFDA lists many heparin labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists atrial fibrillation with embolization as an indication: Atrial fibrillation (AF)
Applies to Recipient not specified People for whom the US label of heparin sodium injection lists an indication: venous thrombosis, pulmonary embolism, atrial fibrillation with embolization, consumptive coagulopathy, arterial and cardiac surgery, peripheral arterial embolism
The US label of Heparin Sodium Injection, in the Fresenius Kabi USA, LLC version dated 2026-04-30 in openFDA, describes heparin as an anticoagulant and lists it for the prophylaxis and treatment of venous thrombosis and pulmonary embolism; the prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or otherwise at risk of thromboembolic disease; atrial fibrillation with embolization; the treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); the prevention of clotting in arterial and cardiac surgery; the prophylaxis and treatment of peripheral arterial embolism; and use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; contraindications, doses, interactions, pregnancy and paediatric use and other warnings were not read. Labels differ between sponsors and change over time, and openFDA lists many heparin labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 26
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record. FDA lists it under 4 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record. FDA lists it under 3 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record. FDA lists it under 6 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record. FDA lists it under 2 brand...
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
Registry trials 16
Record details
- Record id
cardio:heparin- Content hash
1691b3b306aac939c3410424876ab8fcac0345d808c7731132b1b353e951dcc9